Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern

Laura Vangeel(Rega Institute for Medical Research), Dirk Jochmans(Rega Institute for Medical Research)
Antiviral Research
January 24, 2022
Cited by 430


Related Papers